What is at risk? – an environmental health risk assessment related with pharmaceutical substances in drinking water

• Autorzy: Czernych R. , Wrotkowska M. , Muszyńska A. , Wolska L. , Zagożdżon P.
• Języki publikacji: EN

Abstrakty

EN

Constantly increasing rate of drugs’ consumption can be related with environmental abundance of drug substances and their degradation products. Unused and used drugs are often discharged into municipal wastewaters or landfills. Wastewater treatment plants are not able to remove the entire load of drugs. Especially those which occur occasionally or at very low concentrations. Therefore, a variety of pharmaceuticals occur in surface and drinking water sources. A chronic low-level exposure to drugs occurring in a water environment can cause: antibiotic resistance, allergic reactions (eg. Penicillin), cause carcinogenesis (oxytetracycline, furazolidone), nephropathy (gentamicin) and have a negative impact on the natural human intestinal microflora. Therefore, it is not an easy task to assess a common human health effects related with chronic exposure to low doses of active pharmaceutical substances. Nonetheless, such knowledge seems essential in order to undertake preventive actions that would substantially decrease the level of health risk.

Słowa kluczowe

EN

drinking water; pharmaceuticals; health risk assessment; exposure assessment

PL

woda pitna; farmaceutyki; poziom ryzyka zdrowotnego; ocena narażenia

• Wydawca: Foundation for Young Scientists
• Czasopismo: Challenges of Modern Technology
• Rocznik: 2016
• Tom: Vol. 7, no. 2
• Strony: 14--20
• Opis fizyczny: Bibliogr. 38 poz., tab.

Twórcy

autor

Czernych R.

• Deparment of Hygiene and Epidemiology, Faculty of Medicine, Medical University of Gdansk, Dębinki 7 Str., 80-211 Gdansk, Poland

autor

Wrotkowska M.

• Deparment of Hygiene and Epidemiology, Faculty of Medicine, Medical University of Gdansk, Dębinki 7 Str., 80-211 Gdansk, Poland

autor

Muszyńska A.

• Department of Environmental Toxicology, Faculty of Health Sciences, Medical University of Gdansk, Dębowa 23 Str., 80-204 Gdansk, Poland

autor

Wolska L.

• Department of Environmental Toxicology, Faculty of Health Sciences, Medical University of Gdansk, Dębowa 23 Str., 80-204 Gdansk, Poland

autor

Zagożdżon P.

• Deparment of Hygiene and Epidemiology, Faculty of Medicine, Medical University of Gdansk, Dębinki 7 Str., 80-211 Gdansk, Poland

Bibliografia

• [1] Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne. (Dz.U. 2001 nr 126 poz. 1381)
• [2] M.S. Diaz-Cruz, M.J.L. Alda, D. Barcelo, “Environmental behavior and analysis of veterinary and human drugs in soils, sediments and sludge”, Trends Anal. Chem., vol. 22, no. 6, pp. 340-351, June 2003.
• [3] K. Fent, A.A. Weston, D. Caminada, “Ecotoxicology of human pharmaceuticals”, Aquat. Toxicol., vol. 76, no.2, pp. 122-159, Jun. 2006.
• [4] A. Szymonik, J. Lach, „Zagrożenie środowiska wodnego obecnością środków farmaceutycznych”, Inż. i Ochr. Środ., vol. 15, no. 3, pp. 249-263, 2012.
• [5] B. Kasprzyk-Hordern, R.M. Dinsdale, A.J. Guwy, “The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters”, Water Research, vol. 43, no. 2, pp. 363-380, Feb. 2009.
• [6] W.S. Darwish, E.A. Eldaly, M.T. El-Abbasy, et al, “Antibiotic residues in food: the African scenario”, Jpn. J. Vet. Res., 61, pp. 13-22, 2013.
• [7] J.L. Martinez, “Environmental pollution by antibiotics and by antibiotic resistance determinants”, Environ. Pollut., vol. 157, no. 11, pp. 2893- 2902, Nov 2009.
• [8] M. Przeniosło-Siwczyńska, K. Kwiatek, „Dlaczego zakazano stosowania w żywieniu zwierząt antybiotykowych stymulatorów wzrostu?”, Życie Wet., vol. 88, no. 2, pp. 104-108, 2013.
• [9] A. Zabłotni, A. Jaworski, „Sources of antibiotics in natural environments and their biological role”, Hig. Med. Dośw., vol. 68, pp. 1040-1049, Aug 2014.
• [10] U. Guzik, K. Hupert-Kocurek, A. Mazur, et al., „Biotransformacja wybranych niesteroidowych leków przeciwzapalnych w środowisku”, Bromat. Chem. Toksykol. vol. 16, no. 1, pp. 105 – 112, 2013.
• [11] L. Wang, G.G. Ying, J.L. Zhao, et al., “Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China”, Sci Total Environ., vol. 408, no. 16, pp. 3139-3147, Jul 2010.
• [12] A. Helenkar, A. Sebők, G. Zaray, et al., “The role of the acquisition methods in the analysis of thenon-steroidal anti-inflammatory drugs in Danube River by gas chromatography – mass spectrometry”, Talanta, vol. 82, no. 2, pp. 600-607, Jul 2010.
• [13] A. Daneshvar, J. Svanfelt, L. Kronberg, et al., “Winter accumulation of acidic pharmaceuticals in a Swedish River”, Environ Sci Pollut Res Int., vol. 17, no. 4, pp. 908-916, May 2010.
• [14] Y. Valcárcel, S. González Alonso, J.L. Rodríguez-Gil, et al., “Analysis of the presence of cardiovascular and analgesic/antiinflammatory/ antipyretic pharmaceutical in river- and drinking- water of the Madrid Region in Spain”, Chemosphere, vol. 82, no. 7, pp. 1062-1071, Feb 2011.
• [15] M. Stumpf, T.A. Ternes, R.D. Wilken, et al., “Polar drug residue in sewage and natural waters in the state of Rio de Janeiro, Brazil”, Sci. Total Environ., vol. 225, no. 1-2, pp.135–141, Jan 1999.
• [16] B. Kasprzyk-Hordern, A. Dąbrowska, N. Vieno, et al., “Occurrence of acidic pharmaceuticals in the Warta River in Poland”, Chem. Anal., vol. 52, pp. 289-303, 2007.
• [17] S.A. Snyder, B.J. Vanderford, J. Drewes, et al., State of Knowledge of Endocrine Disruptors and Pharmaceuticals in Drinking Water. American Water Works Association Research Foundation Report. 2008.
• [18] A. Nikolaou, S. Meric, D. Fatta, “Occurrence patterns of pharmaceuticals in water and wastewater environments”, Anal. Bioanal. Chem., vol. 387, no. 4, pp. 1225-1234, Feb 2007.
• [19] M. Dudziak, K. Luks-Betlej, „Ocena obecności estrogenówsteroidowych hormonów płciowych w wybranych wodach rzecznych w Polsce”, Ochrona Środowiska, vol. 26, no. 1, pp. 21-24, 2004.
• [20] M. Pedrouzo, F. Borrull, E. Pocurull, et al., “Presence of pharmaceuticals and hormones in waters from sewage treatment plants”, Water Air Soil Pollut., vol. 217, no. 1, pp. 267-281, May 2011.
• [21] M. Velicu, R. Suri, “Presence of steroid hormones and antibiotics in surface water of agricultural, suburban and mixed-use areas”, Environ. Monit. Assess., vol. 154, no. 1-4, pp. 349-359, Jul 2009.
• [22] E. Vulliet, C. Cren-Olive, M.F. Grenier- Loustalot, “Occurrence of pharmaceuticals and hormonesin drinking water treated from surface waters”, Environ Chem Lett., vol. 9, no. 1, pp. 103-114, Mar 2011.
• [23] C.M. de Jongh, J.F. Pascal Kooij, P. de Voogt, et al., “Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water”, Sci Total Environ., vol. 427, pp. 70–77, 2012.
• [24] S.A. Snyder, “Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water”, Ozone: Sci. Eng., vol. 30, pp. 65–69, 2008.
• [25] Q. Zheng, R. Zhang, Y. Wang, et al., “Occurrence and distribution of antibiotics in the Beibu Gulf, China: Impacts of river discharge and aquaculture activities”, Mar Environ Res, vol. 78, pp. 26-33, Jul 2012.
• [26] A. Wasik-Kot, J. Dębska, J. Namieśnik, „Pozostałości środków farmaceutycznych w środowisk: przemiany, stężenia, oznaczenia”, Ecol. Chem. Eng., vol. 10, no. 6, pp. 723-750, 2003.
• [27] D. Perret, A. Gentili, S. Marchese, et al., “Sulphonamide residues in Italian surface and drinking waters: a small scale reconnaissance”, Chromatographia, vol. 63, no. 5, pp. 225–232, 2006.
• [28] US EPA, Risk Assessment Guidance for Superfund, vol. I, Human Health Evaluation Manual. Part A (Interim Final), EPA/540/1-89/002. Office of Emergency and Remedial Response, US Environmental Protection Agency, Washington, DC, 1989.
• [29] US EPA, Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. EPA/630/R-00/002. Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC, 2000.
• [30] Centres of Disease Control and Prevention. Individual Growth Charts [Online]. Available: http://www.cdc.gov/growthcharts/charts.htm
• [31] United States Environmental Protection Agency. Human Health Risk Assessment Protocol for Hazardous Waste Combustion Facilities [Online]. Available: http://www3.epa.gov/epawaste/hazard/tsd/td/combust/riskvol.htm
• [32] M. Cleuvers, “Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects”, Toxicol Lett, vol. 142, no. 3, pp. 185–194, May 2003.
• [33] B. Halling-Sørensen, S. Nors Nielsen ,P.F. Lanzky, et al., “Occurrence, fate and effects of pharmaceutical substances in the environment—a review”, Chemosphere, vol. 36, no. 2, pp. 357– 393, Jan 1998.
• [34] M.L. Farre, I. Ferrer, A. Ginebreda, et al., “Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri”, J Chromatogr A, vol. 938, no. 1-2, pp. 187– 197, Dec 2001.
• [35] D. Camacho-Muñoz, J. Martín, J. L. Santos, “Distribution and Risk Assessment of Pharmaceutical Compounds in River Sediments from Doñana Park (Spain)”, Water Air Soil Pollut., vol. 224, pp. 1665, 2013.
• [36] Y. Kim, K. Choi, J. Jung, et al., “Aquatic toxicity of acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential ecological risks in Korea”, Environ. Int., vol. 33, no. 3, pp. 275–370, Jan 2007.
• [37] R.A. Brain, D.J. Johnson, S.M. Richards, et al., “Effects of 25 pharmaceutical compounds to Lemna gibba using a seven-day static-renewal test”, Environ Toxicol Chem, vol. 23, no. 2, pp. 371– 82, Feb 2004.
• [38] B. Ferrari, N. Paxeus, R. Lo Giudice, et al., “Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac”, Ecotoxicol Environ Saf., vol. 55, no. 3, pp. 359– 370, Jul 2003

Uwagi

PL

Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę.